EcoSystem Executes Agreement for $76 Million in Equity Financing

EcoSystem Executes Agreement for $76 Million in Equity Financing

NEW YORK, N.Y., JULY 30, 2009 – EcoSystem Corporation (OTC Bulletin Board: ESYM) today announced its execution of agreements for the sale of EcoSystem preferred stock and warrants to purchase common stock to five investment funds for $76 million.

Funding under the agreements is expected to occur prior to August 5, 2009 upon the satisfaction by EcoSystem of pre-funding conditions. The funds will be held in a restricted EcoSystem account and will be available for use according to the use of proceeds schedule and other conditions specified in the agreements.

EcoSystem will use the investment proceeds to acquire distressed ethanol production facilities, to acquire other strategically-compatible assets, and to develop and integrate EcoSystem’s Cellulosic Corn™ technologies into EcoSystem’s planned ethanol production facilities.

EcoSystem’s goal is to achieve an annualized renewable fuel production rate of 500 million gallons per year within three years, and to demonstrate market leadership by using its technologies to refine more fuel out of corn for less cost on reduced energy consumption and carbon emitted.

Detailed information regarding this investment is available online at www.eco-system.com in EcoSystem’s July 30, 2009 Form 8K.

Cellulosic Corn™

The corn ethanol industry contributed over $65 billion to the GDP by offsetting 7% of America's fossil fuel needs in 2008. EcoSystem intends to prove that corn has much more to add.

EcoSystem’s view is that the established first generation corn ethanol infrastructure is the only practical pathway in North America to cost-effectively increase the production and use of carbon-neutral biofuels on globally-meaningful scales. To accomplish this in a competitive and environmentally superior way, the installed base of first generation corn ethanol facilities will need to evolve to achieve significantly improved production efficiencies. EcoSystem intends to do just that, and to become a leading low cost and low carbon producer of renewable fuels by leveraging its technology portfolio to acquire and upgrade corn ethanol facilities into increased financial and environmental sustainability while facilitating the convergence of cellulosic and corn ethanol.

EcoSystem’s portfolio of patented and patent-pending Cellulosic Corn™ technologies are designed to achieve the following key goals:

Increase the net energy balance of biofuel derived from corn;
Increase profitability of corn ethanol;
Decrease amount of petroleum burned to make corn derived biofuel;
Increase the nutritional content of corn ethanol co-products;
Reduce, reuse and recycle the carbon emissions of corn ethanol production;
Diversify the biomass mix accepted and produced by traditional corn ethanol facilities;
Decrease the commodity and financial risk profile of corn ethanol;
Standardize corn-friendly cellulosic technology by building on the existing corn ethanol complex; and,
Enhance the competitive positioning of corn ethanol in the domestic and global markets.
About EcoSystem Corporation

EcoSystem’s ambition is to become a leading low cost and low carbon producer of renewable fuels by acquiring and upgrading existing corn ethanol facilities with technologies designed to increase the yield and to reduce the energy consumption and carbon intensity of refining fuel out of corn. Additional information is available online at www.eco-system.com.

Safe Harbor Statement

This press release contains statements that may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of EcoSystem Corporation and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully, and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For more information, please contact:

EcoSystem Corporation
Phone: 212 994 5374
Fax: 646 572 6336
Email: investorrelations@eco-system.com
Web: www.eco-system.com

DNA Vaccine Approach Demonstrates 100% Protection Against Unmatched Flu Virus Strains Currently in Circulation

Inovio Biomedical Universal Influenza Vaccines Demonstrate 100% Protection Against Current Pandemic A/H1N1 Influenza Viruses in Animal Studies

Inovio Consensus DNA Vaccine Approach Demonstrates 100% Protection Against Unmatched Flu Virus Strains Currently in Circulation

SAN DIEGO--(BUSINESS WIRE)--Jul. 29, 2009-- Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today that the company's SynCon™ H1N1 influenza DNA vaccines achieved protection against current circulating swine origin influenza A/H1N1 viruses in animal studies.

Full-text:
http://ir.inovio.com/phoenix.zhtml?c=105128&p=irol-newsArticle_print&ID=1313446&highlight=

CGCA - Potential Reserves of Over 1 Billion Barrels

Potential Reserves of Over 1 Billion Barrels!

from www.passiontolearn.com

CGCA - Max Pozzoni, President. Wallstreet.net Summary:

• Most recent news in Utah.
• Involved in project. Producing oil from sand!
• Leases that belong to Exxon, and partner Entercore. Will secure tar sands.
• Potential reserves of over 1 billion barrels.
• Break even point in lower 20's.
• 12% override with Exxon royalty.
• Oil comes from national resources.
• Extraction from tar pit.
• Environmentally friendly.
• Possible production of several thousands barrels a day.
• Within next 3-6 months.
• Northern Montana option also.

Source: http://tv.wallst.net/3-minute-press/382/1523/CGCA/max-pozzoni/cobra-oil-gas-co/

100% survival rate against an inhaled lethal dose of anthrax - ADLS

Print Page Close Window

Press Release Advanced Life Sciences' Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study CHICAGO, June 23 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), today announced that a second non-human primate study involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin), showed that a 14-day course of Restanza achieved a 100% survival rate against an inhaled lethal dose of anthrax. All of the animals in the study that received 16 mg/kg once-a-day (the human equivalent dose of 300 mg) of Restanza within 24 hours after exposure to anthrax survived while none of the animals that received placebo survived. The study was supported by the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), which is a component of the Department of Health and Human Services (HHS), an agency of the U.S. Government. (Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO) "The successful outcome of the study provides strong evidence of Restanza's life saving potential and underscores its value as a potent new biodefense countermeasure," said Dr. Michael Flavin, Chairman and CEO of Advanced Life Sciences. "When coupled with the positive outcome of the pivotal primate study that we announced in May 2007, we believe that these significant findings complete the regulatory package for Restanza in the post-exposure prophylactic treatment of inhalation anthrax indication. We are looking forward to working with NIAID on the final study report and submitting our data package for regulatory review based on our NDA for Restanza, which is currently under review by the FDA for the treatment of mild-to-moderate community acquired pneumonia (CAP)." Restanza as a Biodefense Countermeasure Advanced Life Sciences is developing Restanza for the post-exposure prophylactic treatment of inhalation anthrax to help protect against human infection from anthrax. In studies conducted by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Restanza was shown to be highly active in vitro against 30 strains of anthrax. In May 2007, a non-human primate study showed that a 30-day course of oral Restanza was 100% protective against a lethal dose of inhaled anthrax as compared to the standard of care, Cipro(R) (ciprofloxacin), which demonstrated 90% protection. The FDA has designated Restanza as an orphan drug for the post-exposure prophylactic treatment of inhalation anthrax, but the FDA has not yet approved the drug for marketing in this or any other indication. In addition to its development in anthrax, Restanza is also being developed to combat other high priority bioterror agents such as Fransicella tularensis (tularemia), Yersinia pestis (plague) and Burkholderia pseudomallei (melioidosis) under a two year, $3.8 million contract with the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense. FDA's "Animal Efficacy Rule" and the Use of Non-Human Primates The "Animal Efficacy Rule" allows for approval of new drug products based on animal data when adequate and well-controlled efficacy studies in humans cannot be ethically conducted because the studies would involve administering a potentially lethal or permanently disabling toxic substance or organism to healthy human volunteers. Approval of a drug under the "Animal Efficacy Rule" is subject to certain post-approval commitments, including the submission of a plan for conducting post-marketing studies, post-marketing restrictions to ensure safe use (if deemed necessary), and product labeling information intended for patient advising that, among other things, indicates the product's approval was based on efficacy studies conducted in animals alone. The non-human primates used in the study referenced above were used to help understand anthrax disease mechanisms and to assess novel approaches for the prophylactic treatment of inhalation anthrax in lieu of human efficacy testing pursuant to FDA's "Animal Efficacy Rule" (21 C.F.R. Section 314.600-650). The study referenced above was carried out in accordance with the Animal Welfare Act (AWA) under the supervision of an Institutional Animal Care and Use Committee (IACUC), which is responsible for enforcing the AWA. About Advanced Life Sciences Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. For more information, please visit us on the web at www.advancedlifesciences.com Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise. SOURCE Advanced Life Sciences Holdings, Inc. CONTACT: Joe Camp of Advanced Life Sciences, +1-630-754-4352, jcamp@advancedlifesciences.com

SPNG - SpongeTech® Delivery Systems, Inc. to Air on QVC

July 23, 2009 02:15 PM Central Daylight Time
SpongeTech® Delivery Systems, Inc. to Air on QVC
SpongeTech® to Offer Uncle Norman’s™ Pet Sponge on QVC
NEW YORK--(BUSINESS WIRE)--SpongeTech® Delivery Systems, Inc., “The Smarter Sponge™”, (OTCBB: SPNG) is pleased to announce that QVC will be featuring SpongeTech®’s Uncle Norman’s™ Pet Sponge on its “Happy Hour” program which is expected to air on July 24, 2009 at 6 pm ET.
QVC will feature SpongeTech®’s Pet Care Product, Uncle Norman’s™ Pet Sponge, the “one-step” pet bath sponge that allows you to bathe your dog, cat or horse with much less hassle. Uncle Norman’s “4 in 1” Pet Sponge is embedded with a gentle shampoo, coat conditioner, odor inhibitor, and 42 special massage bumps to assist the effectiveness of the bath; providing a thorough gentle cleaning for your pet. More importantly, each sponge can be used 8 times or more, depending on the size of your pet. These ingredients are embedded into a hydrophilic foam product that inhibits the bacterial growth in the sponge. Uncle Norman’s™ Pet Sponges are earth-friendly and recyclable too.
SpongeTech®’s COO Steven Moskowitz said, "We are thrilled to be back on with QVC for their Happy Hour program. Our products are being accepted by our television viewers through the airing of our infomercials across the country and we are excited that QVC will introduce our product to additional viewers nationwide.”
QVC is a multi-national corporation specializing in televised home shopping, broadcasting in four major countries to 141 million consumers; revenues generating over $7 billion in international and domestic sales. QVC broadcasts in the US via cable and satellite TV 24 hours a day, 364 days a year to 90 million homes.
SpongeTech®’s Uncle Norman’s™ Pet Sponge will be available through QVC at 1-800-345-1515 or www.QVC.com.
For more information, please contact Investor Relations at 1-877- SPONGE-T, and/or visit the Company’s website at: www.spongetech.com
About SpongeTech® Delivery Systems, Inc.
SpongeTech® Delivery Systems is a company which designs, produces, and markets unique lines of reusable cleaning products for Car Care, Child Care, Home Care and Pet Care usages. These sponge-like products utilize SpongeTech®'s proprietary, patent (and patent-pending) technologies and other technologies involving hydrophilic (liquid absorbing) foam, polyurethane matrices or other ingredients. The Company's sponge-like products are pre-loaded with specially formulated ingredients such as soap, conditioner and/or wax that are released when the sponge is soaked and applied to a surface with minimal pressure. SpongeTech® is currently exploring additional applications for its technology in the health, beauty, and medical markets. SpongeTech® Delivery Systems, Inc. intends to globally brand its products as The Smarter Sponge™ .
Safe Harbor Statement
Under The Private Securities Litigation Reform Act of 1995: The statements in this presentation that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements may not occur. Additional risks and uncertainties are set forth in the Company's Annual Report on Form 10-KSB for the year ended May 31, 2008, the Company's Quarterly Report on Form 10-QSB for the Third quarter ended February 28, 2009. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.
Contacts
SpongeTech® Delivery Systems, Inc.Investor Relations:Bill Young, 1-877-776-6438wayoung55@aol.com or info@spongetech.comorConnecting Markets GmbHToll Free: +0800 100 42 92Fon: +49 (0) 69 21 65 59 10Fax: +49 (0) 69 21 65 59 11info@cmir.de
Permalink: http://www.businesswire.com/news/home/20090723006063/en